A Phase 1 Study of PRT2527, a Selective CDK9 Inhibitor, as Monotherapy and in Combination With Zanubrutinib in Relapsed / Refractory Lymphoid Malignancies: Updated Analysis 

Wojciech Jurczak, Clementine Sarkozy, Katharine L. Lewis, Geoffrey Shouse, Eliza A. Hawkes, Won Seog Kim, Monica Tani, François Lemonnier, Sarit E. Assouline, Franck Morschhauser, Bruce D. Cheson, Catherine S. Diefenbach, Gareth P. Gregory, Talha Munir, Petra Langerbeins, Constantine S. Tam, Gerardo Musuraca, Craig A. Portell, Anastasios Stathis, Young Rok Do, Jennifer Xavier, Muhtarjan Osman, Siminder K. Atwal, Jane Huang, Pier Luigi Zinzani